In the stock market on the 21st, most of the stock prices of domestic pharmaceutical companies known to be developing a treatment for Corona 19 surged. It is interpreted as the fact that the Korean pharmaceutical company is moving to a treatment that is being developed by a domestic pharmaceutical company as the time to introduce the Corona 19 vaccine in Korea is delayed than expected.
On that day, Daewoong Pharmaceutical went directly to the upper limit with the opening and ended at 275,500 won. Chong Kun Dang also ended at 261,000 won, up 7.19% from the previous trading day. In December, Daewoong Pharmaceutical surged 166% and Chong Kundang rose 50%. The reason why Daewoong Pharmaceutical’s stock price soared to the price limit on the same day was due to the news that the Corona 19 treatment’DWRX2003 (ingredient name niclosamide)’, which is being developed, has been preliminarily selected as a project to support the construction of production equipment by the Korea Health Industry Development Institute. This news is interpreted as the production of Daewoong Pharmaceutical’s COVID-19 treatment in the market.
Looking at the development stage, Daewoong Pharm is currently conducting a global phase 2 clinical trial,’Hoistar’ is fast. The oral drug’Hoystar’ is on the market, and its strength is that it has high ease of administration and low safety concerns. As a result of prescribing’Hoystar’ to mild Corona 19 patients in Korea, Daewoong Pharmaceutical has secured the results that it has better anti-inflammatory effects and less adverse reactions than’Kaletra’, a human immunodeficiency virus (HIV) treatment used as a treatment for Corona 19. . It plans to complete the phase 2 clinical trial and apply for conditional permission in January next year.
Chong Kun Dang is developing’Napabeltan’ (ingredient name Napamostat), which is used as a treatment for acute pancreatitis or as an anticoagulant for blood, as a treatment for Corona 19. Napamostat has a mechanism to inhibit the proteolytic enzyme’TMPRSS2′, which is known to play a major role in the cell penetration process of the Corona 19 virus. Chong Kun Dang signed a joint research agreement with Pasteur Korea Research Institute and Korea Atomic Energy Research Institute in June and initiated phase 2 clinical trials in Korea and Russia. Recently, with approval from the Australian Food and Drug Administration to participate in ASCOT, a large-scale phase 3 clinical trial project to end COVID-19, the scope of clinical trials has been expanded to 7 countries including Korea, Russia, Mexico, Senegal, Australia, New Zealand, and India.
Chong Kun Dang aims to complete the medication for patients who participated in the Napamostat clinical trial within this year, secure the results in January next year, and then apply for conditional permission.
Jin Hong-guk, a researcher at Korea Investment & Securities Co., advised, “It is necessary to invest while confirming which clinical stage the treatment being developed is going through.”
[김기철 기자]
[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]